© 2020 MJH Life Sciences and OncLive. All rights reserved.
March 03, 2014
Brian Leyland-Jones, MBBS, PhD, director, Edith Sanford Breast Cancer Research, discusses the development of breast cancer risk assessment tools.
December 07, 2012
Brian Leyland-Jones, MBBS, PhD, discusses results from the phase III HERA trial that compared 2 years of adjuvant trastuzumab to the standard 1 year in HER2-postive early-stage breast cancer.
February 20, 2012
Dr. Brian Leyland-Jones from Winship Cancer Institute Discusses Genome Sequencing